Zhu-Xu Zhang1, Xuyan Huang, Jifu Jiang, Dameng Lian, Wei-Ping Min, Weihua Liu, Aaron Haig, Anthony M Jevnikar. 1. 1 Matthew Mailing Centre for Translational Transplantation Studies, Lawson Health Research Institute, London Health Sciences Centre, London, UK. 2 Departments of Medicine, Surgery and Pathology, University of Western Ontario, London, Ontario, Canada. 3 Address correspondence to: Zhu-Xu Zhang, Ph.D., London Health Sciences Centre,B4-231, 339 Windermere Road, London, Ontario, Canada N6A 5A5.
Abstract
BACKGROUND: Approximately 50% of cardiac transplants fail in the long term, and currently, there are no specific treatments to prevent chronic rejection. In the clinic, donor cardiac graft ischemia time is limited to within a few hours and correlates with delayed graft function and organ failure. It is still unknown how ischemic injury negatively influences allograft function over the long term despite advances in immunosuppression therapy. METHODS: Allogeneic cardiac grafts were stored at 4 °C for 4 hr before being transplanted into T/B cell-deficient Rag(-/-) mice or T/B/natural killer (NK) cell-deficient γc(-/-)Rag(-/-) mice. Grafts were harvested 60 days after transplantation and indicators of chronic allograft vasculopathy (CAV) were quantified. RESULTS: We have found that cold ischemia of cardiac grafts induces CAV after transplantation into Rag1(-/-) mice. Interestingly, cold ischemia-induced CAV posttransplantation was not seen in T/B/NK cell-deficient γc(-/-)Rag(-/-) mice. However, cardiac grafts in γc(-/-)Rag(-/-) mice that received an adoptive transfer of NK cells developed CAV, supporting the role of NK cells in CAV development. Analysis of various cytokines that contribute to NK cell function revealed high interleukin (IL)-6 expression in cardiac grafts with CAV. In addition, IL-6-deficient cardiac grafts did not develop CAV after transplantation into allogeneic Rag(-/-) mice. CONCLUSION: These data demonstrate that cold ischemia and NK cells play critical roles in the development CAV. Natural killer cells and injured grafts may play a reciprocal role for CAV development in an IL-6-independent manner. Specific therapeutic strategies may be required to attenuate NK cell contribution to chronic cardiac rejection.
BACKGROUND: Approximately 50% of cardiac transplants fail in the long term, and currently, there are no specific treatments to prevent chronic rejection. In the clinic, donor cardiac graft ischemia time is limited to within a few hours and correlates with delayed graft function and organ failure. It is still unknown how ischemic injury negatively influences allograft function over the long term despite advances in immunosuppression therapy. METHODS: Allogeneic cardiac grafts were stored at 4 °C for 4 hr before being transplanted into T/B cell-deficient Rag(-/-) mice or T/B/natural killer (NK) cell-deficient γc(-/-)Rag(-/-) mice. Grafts were harvested 60 days after transplantation and indicators of chronic allograft vasculopathy (CAV) were quantified. RESULTS: We have found that cold ischemia of cardiac grafts induces CAV after transplantation into Rag1(-/-) mice. Interestingly, cold ischemia-induced CAV posttransplantation was not seen in T/B/NK cell-deficient γc(-/-)Rag(-/-) mice. However, cardiac grafts in γc(-/-)Rag(-/-) mice that received an adoptive transfer of NK cells developed CAV, supporting the role of NK cells in CAV development. Analysis of various cytokines that contribute to NK cell function revealed high interleukin (IL)-6 expression in cardiac grafts with CAV. In addition, IL-6-deficient cardiac grafts did not develop CAV after transplantation into allogeneic Rag(-/-) mice. CONCLUSION: These data demonstrate that cold ischemia and NK cells play critical roles in the development CAV. Natural killer cells and injured grafts may play a reciprocal role for CAV development in an IL-6-independent manner. Specific therapeutic strategies may be required to attenuate NK cell contribution to chronic cardiac rejection.
Authors: Kristofor Glinton; Matthew DeBerge; Emily Fisher; Samantha Schroth; Arjun Sinha; Jiao-Jing Wang; J Andrew Wasserstrom; Mohammed Javeed Ansari; Zheng Jenny Zhang; Matthew Feinstein; Joseph R Leventhal; Joseph M Forbess; Jon Lomasney; Xunrong Luo; Edward B Thorp Journal: J Heart Lung Transplant Date: 2021-03-13 Impact factor: 13.569
Authors: Herwig P Moll; Andy Lee; Clayton R Peterson; Jesus Revuelta Cervantes; Brandon M Wojcik; Anshul Parulkar; Alessandra Mele; Philip J LoGerfo; Jeffrey J Siracuse; Eva Csizmadia; Cleide G da Silva; Christiane Ferran Journal: Transplantation Date: 2016-11 Impact factor: 4.939
Authors: Priscila de Matos Silva; Julia Bier; Lisiery Negrini Paiatto; Cassia Galdino Albuquerque; Caique Lopes Souza; Luis Gustavo Romani Fernandes; Wirla Maria da Silva Cunha Tamashiro; Patricia Ucelli Simioni Journal: J Immunol Res Date: 2015-10-12 Impact factor: 4.818